Fish oil is one of the best-selling supplements in the world, and one of its most popular selling points is eye health. Walk into any pharmacy, scroll through Amazon, or read the back of almost any omega-3 bottle and you'll find some version of the claim: this helps with dry eyes. Millions of people buy into it every year, often spending $30 to $60 a month on capsules they believe are relieving their symptoms.
A large systematic review covering 57 randomized controlled trials and more than 6,600 dry eye patients has now put that claim to a rigorous test. The results are worth reading carefully before you reorder.
What the Research Actually Found
The review pooled data from 57 randomized trials specifically examining marine omega-3 supplementation in people diagnosed with dry eye disease. That's a substantial evidence base. Dry eye is a common condition affecting hundreds of millions of people globally, and the supplement market around it is enormous.
Across those trials, marine omega-3 supplementation reduced symptom scores by an average of 4.4 points. It also improved tear break-up time (a standard clinical measure of tear film stability) by about 1.3 seconds.
Both of those numbers sound like progress. The problem is context. Researchers use a threshold of 7 points on standard symptom scales to define what patients themselves consider a meaningful improvement. At 4.4 points, fish oil falls well short of that bar. A 1.3-second improvement in tear break-up time is similarly modest. It's detectable in a statistical model, but it's unlikely to be something you notice in daily life.
Small Numbers and Inconsistent Results
The average effect size is only part of the story. Across those 57 trials, results were notably inconsistent. Some studies showed more substantial benefits, others showed almost none. That kind of variability across a large trial pool is a red flag. It suggests the effect isn't reliable or predictable, and it makes it very hard to tell which patients, if any, are the ones actually responding to the supplement.
Inconsistency across trials can stem from several factors: differences in dosage, differences in the ratio of EPA to DHA, variations in how dry eye was diagnosed, how long patients were followed, and what else they were doing for their eyes during the study period. When effects fluctuate this much depending on how a study was run, it's a sign that the treatment isn't doing heavy lifting on its own.
This matters because marketing for omega-3 supplements rarely communicates uncertainty. It presents the benefit as established and clinically significant. The evidence says otherwise.
Why This Doesn't Mean Omega-3s Are Worthless
It's worth being precise here, because nuance gets lost quickly in health conversations. This review doesn't say fish oil has no effect on dry eyes. It says the average effect observed across a very large body of evidence is small and falls below the threshold most patients would notice. That's a very different statement than "don't bother."
Omega-3 fatty acids have documented roles in inflammation modulation, membrane structure, and cardiovascular health. Some of that biology is genuinely relevant to ocular surface health. The review doesn't overturn the mechanism. It just shows that the real-world effect in clinical trials doesn't match what the mechanism alone might predict.
It's also possible that subgroups of patients respond better than the average. People with more severe deficiency in omega-3s, or those with specific inflammatory subtypes of dry eye disease, might see more benefit. That kind of precision hasn't been well-established in the current evidence base, but it's a reasonable area for further investigation rather than a reason to assume everyone benefits equally.
If you're already taking omega-3s for cardiovascular reasons, or because a clinician recommended them for another purpose, this finding doesn't change that calculus. But if dry eye relief is your primary motivation and you're spending meaningful money on it, this evidence should recalibrate your expectations.
For context on how to think critically about supplement evidence more broadly, the evidence on whether multivitamins actually improve health follows a similar pattern: plausible biology, aggressive marketing, and clinical trial results that consistently underperform the hype.
The Marketing Gap Is the Real Problem
The supplement industry in the US alone generates over $50 billion annually. Eye health supplements are one of the fastest-growing subcategories. Fish oil brands frequently cite omega-3 research on their labels and websites in ways that imply proven, significant benefit.
What those claims rarely include is the actual effect size, the clinical meaningfulness threshold, or any acknowledgment that results across trials are inconsistent. That gap between what the marketing implies and what the evidence shows is worth naming directly.
It also matters because it's not just about wasted money. People who believe a supplement is handling their dry eye symptoms may delay or avoid more effective treatments: prescription eye drops, lid hygiene protocols, environmental modifications, or in-office procedures that have stronger evidence behind them. The cost of misplaced confidence in a supplement isn't only financial.
If you're buying supplements and wondering whether the label reflects the actual research, the problem with supplement label accuracy in 2026 is worth understanding before your next purchase.
What You Should Actually Do If You Have Dry Eyes
Dry eye disease is not a single condition. It has multiple subtypes, multiple contributing causes, and responds differently to different interventions depending on what's driving it for a particular person. That complexity is why self-treating with supplements based on marketing claims tends to produce disappointing results.
If your dry eye symptoms are persistent or affecting your daily life, the most evidence-supported step is a proper evaluation by an ophthalmologist or optometrist who can identify your specific subtype. That evaluation should drive treatment decisions, not label copy on a supplement bottle.
Some practical factors that do have stronger evidence for dry eye management include:
- Screen break habits. Reduced blink rate during screen use is a well-documented contributor to dry eye symptoms. Structured breaks help.
- Humidity control. Low-humidity indoor environments, particularly in air-conditioned or heated spaces, significantly worsen symptoms for many people.
- Warm compresses and lid hygiene. For meibomian gland dysfunction (a common subtype), these interventions have meaningful clinical backing.
- Preservative-free artificial tears. For symptom management, high-quality lubricating drops used consistently often outperform supplements in head-to-head comparisons.
- Prescription options. Cyclosporine drops and lifitegrast have regulatory approval and randomized trial evidence behind them for moderate to severe dry eye.
None of these are as simple to sell as a capsule. But the evidence behind them is considerably more robust.
A Note on Omega-3 Dosage and Quality
One complicating factor in interpreting the dry eye trials is that omega-3 dosages and formulations varied widely. Not all fish oil supplements are equivalent. EPA and DHA concentrations differ substantially between products, and absorption varies depending on whether the formula uses triglyceride or ethyl ester form.
This is a recurring problem in supplement research: inconsistent products make it harder to isolate what's working. It also means that even if higher-dose, better-absorbed formulations do show more reliable effects in future trials, that won't apply to most of what's currently on shelves.
Understanding the difference between food-based nutrient sources and supplement forms is relevant here too. The evidence on bioavailability and real-world effects often diverges depending on the source. How food versus supplements differ in nutrient delivery is a useful frame for thinking about this across categories, not just omega-3s.
The Broader Lesson Here
Fifty-seven randomized trials and more than 6,600 patients is not a small sample. When that volume of evidence points to an effect that falls below what patients themselves consider meaningful, and when the results are inconsistent across trials, the rational conclusion is skepticism, not confidence.
That doesn't make omega-3s a scam. It makes the specific marketing claim that fish oil reliably relieves dry eyes an overclaim. There's an important difference between those two things, and it's worth holding onto that distinction when you're deciding where to spend your supplement budget.
Wellness decisions are often made in an information environment that's shaped more by marketing than by clinical evidence. The goal isn't to dismiss every supplement, but to match your expectations to what the actual evidence supports. In this case, the evidence supports modest, inconsistent effects that most patients are unlikely to notice. That's the honest picture, and you deserve to have it.
For a broader look at how to evaluate supplement claims critically, reviewing how clinical evidence plays out across supplement categories offers useful context for making more informed decisions.